Filtered By:
Specialty: Neurology
Drug: Fluoxetine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 28 results found since Jan 2013.

Fluoxetine or Venlafaxine for Early Post Stroke Depression
Conclusions: PSD in the early phase affects a substantial number of the stroke patients. Venlafaxine has got a better outcome and adverse event profile compared to fluoxetine in this group of patients. However, larger multicenter studies will provide more helpful data in this area.
Source: Neurology India - December 19, 2022 Category: Neurology Authors: Vivek K Nambiar J Parvathy Tania M Philip K Abhijith S Sreeni Naveen K Panicker Amrutha V Ajai TS Dhanya Source Type: research

MEASURING AMBULATION, MOTOR, AND BEHAVIORAL OUTCOMES WITH POST-STROKE FLUOXETINE IN TANZANIA: THE Phase II MAMBO TRIAL
We test the safety of fluoxetine post-ischemic stroke in Sub-Saharan Africa. Adults with acute ischemic stroke, seen
Source: Journal of Stroke and Cerebrovascular Diseases - March 20, 2022 Category: Neurology Authors: Emmanuel Massawe, Notburga A. Mworia, Seif Ismail, Dylan R. Rice, Andre C. Vogel, Boniface Kapina, Novath Mukyanuzi, Deus C. Buma, Jef Gluckstein, Michael Wasserman, Susan E. Fasoli, Faraja Chiwanga, Farrah J. Mateen, Kigocha Okeng'o Source Type: research

Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania
Post-stroke fluoxetine trials are primarily conducted in high-income countries. We characterize post-ischemic stroke depression in fluoxetine-treated and -untreated study participants in urban Tanzania.
Source: Journal of Stroke and Cerebrovascular Diseases - November 2, 2021 Category: Neurology Authors: Dylan R. Rice, Kigocha Okeng'o, Emmanuel Massawe, Seif Ismail, Notburga A. Mworia, Faraja Chiwanga, Boniface Kapina, Michael Wasserman, Farrah J. Mateen Source Type: research

The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis
Conclusions: Fluoxetine and citalopram can promote motor recovery in non-depressed patients with acute stroke, but it is necessary to pay attention to the possible AEs of fluoxetine, such as hyponatremia, seizure and fracture.Systematic Review Registration: PROSPERO, identifier [CRD42021227452].
Source: Frontiers in Neurology - October 20, 2021 Category: Neurology Source Type: research

Final Word on SSRI for Post-Stroke Depression? Final Word on SSRI for Post-Stroke Depression?
The antidepressant fluoxetine does not prevent or alleviate post-stroke depression, new findings from a randomized, placebo-controlled trial confirm.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - August 12, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Poststroke Selective Serotonin Reuptake Inhibitors
In the community, major risk factors for depression include sex, advancing age, lower income, employment status, and illnesses such as stroke that result in disability and affect income, employment, and social status. Poststroke depression affects 1 in every 3 patients in the first year after stroke occurrence and thereafter. Important general treatments for depression include the selective serotonin reuptake inhibitors; these compounds have also been suggested to modulate motor and functional recovery after stroke. The FLAME (Fluoxetine for Motor Recovery After Acute Ischaemic Stroke) trial kindled interest in treatment w...
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery
This randomized clinical trial investigates whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by symptoms of depression after stroke.
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic
Conclusion: Among patients with stroke, early initiation of fluoxetine did not result in improved functional recovery. Lower rates of depression were observed in the fluoxetine-treated group; however these patients experienced higher rates of bone fracture.
Source: The Neurologist - May 1, 2021 Category: Neurology Tags: Critically Appraised Topics Source Type: research

Is Fluoxetine Good for Subacute Stroke? A Meta-Analysis Evidenced From Randomized Controlled Trials
Conclusion: In post-stroke treatment, fluoxetine did not improve participants' mRS and NIHSS but improved FMMS and BI. This difference could result from heterogeneities between the trials: different treatment duration, clinical scales sensitivity, patient age, delay of inclusion, and severity of the deficit.
Source: Frontiers in Neurology - March 22, 2021 Category: Neurology Source Type: research

Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial.
CONCLUSIONS AND CLINICAL IMPLICATIONS: Consistent with other trials based on the FOCUS protocol, fluoxetine did not improve motor recovery or general stroke outcome at six and 12 months in the Polish cohort studied. However, patients receiving fluoxetine required therapy with additional antidepressant medication less frequently. PMID: 33373036 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - December 29, 2020 Category: Neurology Authors: Bembenek JP, Niewada M, Kłysz B, Mazur A, Kurczych K, Głuszkiewicz M, Członkowska A Tags: Neurol Neurochir Pol Source Type: research

Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial
Publication date: August 2020Source: The Lancet Neurology, Volume 19, Issue 8Author(s): Erik Lundström, Eva Isaksson, Per Näsman, Per Wester, Björn Mårtensson, Bo Norrving, Håkan Wallén, Jörgen Borg, Martin Dennis, Gillian Mead, Graeme J Hankey, Maree L Hackett, Katharina S Sunnerhagen
Source: The Lancet Neurology - July 21, 2020 Category: Neurology Source Type: research

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial
Publication date: August 2020Source: The Lancet Neurology, Volume 19, Issue 8Author(s): Graeme J. Hankey, Maree L. Hackett, Osvaldo P. Almeida, Leon Flicker, Gillian E. Mead, Martin S. Dennis, Christopher Etherton-Beer, Andrew H. Ford, Laurent Billot, Stephen Jan, Thomas Lung, Veronica Murray, Erik Lundström, Craig S. Anderson, Robert Herbert, Gregory Carter, Geoffrey A. Donnan, Huy-Thang Nguyen, John Gommans, Qilong Yi
Source: The Lancet Neurology - July 21, 2020 Category: Neurology Source Type: research

Effect of fluoxetine on HIF-1 α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion.
Effect of fluoxetine on HIF-1α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion. Exp Neurol. 2020 Apr 12;:113312 Authors: Hu Q, Liu L, Zhou L, Lu H, Wang J, Chen X, Wang Q Abstract Fluoxetine is one of the most promising drugs for improving clinical outcome in patients with ischemic stroke. This in vivo study investigated the hypothesis that fluoxetine may affect HIF-1α-Netrin/VEGF cascade, angiogenesis and neuroprotection using a rat model of transient middle cerebral artery occlusion (tMCAO). The rats were given fluoxetine or salin...
Source: Experimental Neurology - April 11, 2020 Category: Neurology Authors: Hu Q, Liu L, Zhou L, Lu H, Wang J, Chen X, Wang Q Tags: Exp Neurol Source Type: research

Effect of Electroacupuncture on Relieving Central Post-Stroke Pain by Inhibiting Autophagy in the Hippocampus.
CONCLUSION: EA may inhibit autophagy in the hippocampus by reducing β-catenin/COX-2 protein expression and effectively alleviating CPSP. SIGNIFICANCE: Statement Previous studies have found that EA can reduce the expression of NK-1R in damaged rats by inhibition of COX-2 and β-catenin loops, which controls the activation of glial cells in the damaged area and the apoptosis of neuronal cells, and alleviated pain. In the male SD rat model, we evaluated this effect that EA inhibits autophagy in the hippocampus by reducing β-catenin/COX-2 protein expression in the brain tissue. In addition, we assessed expression levels...
Source: Brain Research - January 23, 2020 Category: Neurology Authors: Zheng L, Li XY, Huang FZ, Zhang XT, Tang HB, Li YS, Kevin Zhang W, Li XJ, Tian GH Tags: Brain Res Source Type: research

MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial
Sub-Saharan Africa has a high stroke incidence and post-stroke morbidity. An inexpensive pharmacological treatment for stroke recovery would be beneficial to patients in the region. Fluoxetine, currently on the World Health Organization Essential Medicines List, holds promise as a treatment for motor recovery after ischemic stroke, but its effectiveness is controversial and untested in this context in Sub-Saharan Africa.
Source: Journal of the Neurological Sciences - November 5, 2019 Category: Neurology Authors: AndreC. Vogel, Kigocha Okeng'o, Faraja Chiwanga, Seif Sharif Ismail, Deus Buma, Lindsay Pothier, Farrah J. Mateen Source Type: research